Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04896476
Other study ID # IDE-F1-2021
Secondary ID R44HL147423
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date January 21, 2022
Est. completion date June 6, 2025

Study information

Verified date November 2023
Source Sonavex, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Multi-center trial to assess the feasibility and safety of the EchoMark LP and the EchoMark diagnostic ultrasound system for assessing AV fistula blood flow, diameter, and depth.


Description:

This is a prospective, multi-center, single-arm, non-blinded clinical trial designed to evaluate the feasibility and safety of the EchoMark and the EchoSure in subjects undergoing new upper arm autologous arteriovenous fistula creation who require hemodialysis. All subjects will provide informed consent prior to undergoing any study procedures. The study will consists of multiple follow-up visits during the 52 week duration.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 20
Est. completion date June 6, 2025
Est. primary completion date June 20, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: 1. Males or non-pregnant, non-breastfeeding females = 18 years of age but < 85 years of age at the time of informed consent 2. Subject is able and willing to provide written informed consent prior to receiving any non-standard of care, protocol specific procedures 3. Subject is willing and capable of complying with all required follow-up visits 4. Subject and/or Care Team agree that the distance and transportation resources from the subject's home to the clinic are reasonable for study participation and compliance 5. Subject has an estimated life expectancy > 18 months 6. Subject is ambulatory (cane or walker are acceptable) 7. Subjects presenting for upper arm autologous arteriovenous fistula creation 8. Vein diameter > 2.5 mm at the antecubital fossa via imaging 9. Artery diameter > 3 mm via imaging 10. Subject is not participating in another investigational clinical trial that has not met its primary endpoint. Participation in a post-market registry is acceptable. Exclusion Criteria: 1. Subjects receiving a forearm fistula. 2. Subject has history of Steal Syndrome. 3. Subject who is immunocompromised or immunosuppressed. 4. Subject has had three previous failed AV fistulae for hemodialysis access 5. Subjects expecting to undergo major surgery within 60 days from the EchoMark implantation. 6. Known or suspected active infection on the day of the index procedure. 7. Subjects who had infection(s) in the 30-day window prior to EchoMark placement to reduce the likelihood of partially treated infections that can seed the device and fistula 8. Subjects with diagnosed bleeding disorder, thrombocytopenia (platelet count <50,000), hypercoagulability, and history of recurrent deep vein thrombosis not related to AV access 9. Subjects with active malignancy 10. Subjects with a history of poor compliance with the dialysis protocol 11. Subjects with a known or suspected allergy to any of the device materials 12. Subjects with an existing fistula or graft 13. Subjects who are pregnant, plan to become pregnant, or are breastfeeding.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
EchoMark
The EchoMark is to be secured a minimum of 3 cm away from the anastomosis.

Locations

Country Name City State
United States Surgical Specialist of Charlotte Charlotte North Carolina
United States Trinity Research Group Dothan Alabama
United States Michgan Vascular Center Flint Michigan
United States SKI Vascular Center Peoria Arizona

Sponsors (2)

Lead Sponsor Collaborator
Sonavex, Inc. National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Comparison of EchoSure and duplex measurements of flow Only duplex images that pass the CoreLab quality control check will be included in the assessment. 6 Months
Other Comparison of EchoSure and duplex measurements of diameter Only duplex images that pass the CoreLab quality control check will be included in the assessment. 6 Months
Other Comparison of EchoSure and duplex measurements of depth Only duplex images that pass the CoreLab quality control check will be included in the assessment. 6 Months
Other Time to radiographic maturation defined as the number of days from baseline procedure to date of radiographic maturation (date of ultrasound imaging, as adjudicated by the CEC). Radiographic maturation is defined as a fistula with volume flow of 500mL/min and 5mm diameter. 12 Months
Other Time to clinical maturation defined as the number of days from baseline procedure to date of clinical maturation. Clinical maturation is defined as 75% of dialysis sessions with successful 2 needle cannulation. Date of clinical maturation is defined as first date of the 4-week window when clinical maturation is achieved. 12 Months
Other Radiographic maturation success rate defined as the percentage of subjects that achieve radiographic maturation (as determined by the physician and adjudicated by the CEC) by end of study. Radiographic maturation is defined as a fistula with 500mL/min and 5mm diameter. 12 Months
Other Clinical maturation success rate defined as the percentage of subjects that achieve clinical maturation by end of study. Date of clinical maturation is defined as first date of the 4-week window when clinical maturation is achieved. 12 Months
Other 6-month patency rate defined by the status (yes/no) of an arteriovenous dialysis access with detectable blood flow through and beyond the anastomosis shown by either an imaging modality or physical examination (presence of a palpable thrill or audible bruit along some point of the arteriovenous dialysis access beyond the arteriovenous anastomosis). 6 Months
Other 12-month patency rate defined by the status (yes/no) of an arteriovenous dialysis access with detectable blood flow through and beyond the anastomosis shown by either an imaging modality or physical examination (presence of a palpable thrill or audible bruit along some point of the arteriovenous dialysis access beyond the arteriovenous anastomosis). 12 Months
Other Occurrence of events occurring within 30 days of implantation that require reinterventions (open or endovascular), hospitalizations, or prolongation of existing hospitalization. 30 Days
Other Occurrence of reported reduction of blood flow that prevents the ability to cannulate or requires further assessment and/or intervention from baseline procedure to 12 months. 12 Months
Other Occurrence of the reported inability to cannulate fistula beginning once the fistula is deemed radiographically and clinically mature to 12 months. 12 Months
Other Occurrence of the development of steal syndrome from baseline to 12 months. 12 Months
Other Occurrence of bleeding requiring surgical intervention (including PRBC transfusion) from baseline to 12 months. 12 Months
Other Occurrence of infiltration requiring procedural intervention from baseline to 12 months. 12 Months
Other Occurrence of hematoma requiring procedural intervention from baseline to 12 months. 12 Months
Other Occurrence of the inability to use the EchoSure component of the system from baseline to 4 months Due to:
Migration of the EchoMark device
Early resorption of the EchoMark device as defined as breakdown of the EchoMark shape prior to 4 months from index procedure.
4 Months
Other Occurrence of pain related to the study devices from baseline to 12 months 12 Months
Other Occurrence of infection (not limited to infection requiring implant explanation) from baseline to 12 months 12 Months
Other Occurrence of infection confirmed by either implant explanation or purulent fluid on pathologic assessment during incision and drainage beginning at baseline to 12 months 12 Months
Other Composite of new major device related adverse events (MAEs) at 12 months post EchoMark LP implantation, as adjudicated by the Clinical Events Committee (CEC). The proportion of subjects with device success and free from device- and/or procedure related
SAEs (per CEC adjudication) at 12 months. The summaries for each individual safety data point will also be provided, including:
Device or procedure-related death
Device related infection
Device related interventions
Device related hospitalizations
Fistula failure
Fistula rupture
Aneurysm
12 Months
Primary Primary Safety Endpoint Composite of new major device related adverse events (MAEs) at 30 days post EchoMark implantation, as adjudicated by the Clinical Events Committee (CEC) including:
Device or procedure-related death
Device related infection
Device related interventions
Device related hospitalizations
Fistula failure
Fistula rupture
Aneurysm
30 Days
Primary Primary Feasibility Endpoint Rate of Technical Success defined as the successful implantation of the EchoMark implant and the ability to determine blood flow, diameter, and depth measurements using the EchoSure diagnostic ultrasound system. Technical success will be assessed from baseline to 4 months. 6 Months
See also
  Status Clinical Trial Phase
Completed NCT03246984 - VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ N/A
Completed NCT03545113 - Graft-first Versus Fistula-first in Older Patients With End-stage Kidney Disease N/A
Recruiting NCT05100017 - Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S/P Ureteroscopy Procedure N/A
Recruiting NCT04559321 - Holmium Vs Trilogy Kidney Stones GUY's 1-2 Phase 3
Recruiting NCT05036850 - China Kidney Patient Trials Network
Completed NCT04037436 - Functional Exercise and Nutrition Education Program for Older Adults N/A
Active, not recruiting NCT01529658 - Renal Hypothermia During Partial Nephrectomy N/A
Completed NCT01679587 - Dose Escalation Study to Investigate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY85-3934 in Subjects With Chronic Kidney Disease (CKD) Phase 1
Completed NCT01155141 - Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH Phase 4
Completed NCT00755690 - Study of Dietary Phosphate and Mineral Homeostasis in Early Chronic Kidney Disease N/A
Recruiting NCT05759754 - Effects of Traditional Chinese Medicine (GSJYF) in Children With Inherited Proteinuric Kidney Disease N/A
Completed NCT03213158 - Ixazomib for Desensitization Phase 2
Active, not recruiting NCT02237352 - Mechanisms of Diabetic Nephropathy in Ecuador
Recruiting NCT06067867 - Kidney and Pregnancy Registry
Recruiting NCT04110080 - Enhanced Recovery After Surgery in Kidney Transplant Donors N/A
Active, not recruiting NCT04876963 - HOLT-ED: Holter-monitoring in End-stage Renal Disease
Enrolling by invitation NCT05324878 - Honoring Individual Goals and Hopes: Implementing Advance Care Planning for Persons With Kidney Disease on Dialysis
Not yet recruiting NCT03899298 - Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions Phase 1
Active, not recruiting NCT04631965 - Healthcare Transition of Adolescents With Chronic Health Conditions
Completed NCT03394859 - Electronic Medical Records and Genomics (eMERGE) Phase III